Minfeng Chen
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Molecular Biology top 10%
- RNA modifications and cancer
- Cancer-related gene regulation
- Epigenetics and DNA Methylation
Papers in
-
- Angiogenesis and VEGF in Cancer 5
-
- Cancer-related molecular mechanisms research 8
- Cancer, Hypoxia, and Metabolism 5
- Co-authors
- Dongmei Zhang (24 shared papers)Wen‐Cai Ye (21 shared papers)Lijuan Deng (10 shared papers)Xiongbing Zu (21 shared papers)Zhe‐Sheng Chen (4 shared papers)Maohua Huang (13 shared papers)Ming Qi (3 shared papers)Jinbo Chen (8 shared papers)
- Journals
- European Journal of Nuclear Medicine and Molecular Imaging (4 papers)BMC Cancer (4 papers)Orphanet Journal of Rare Diseases (3 papers)Cancer Letters (3 papers)PLoS ONE (2 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Minfeng Chen
80 papers receiving 2.3k citations
Minfeng Chen's Hit Papers
Peers
Comparison fields: 5 of 105
- Cancer Research 514
- Molecular Biology 1.1k
- Oncology 353
- Pharmacology 111
- Immunology 232
Countries citing papers authored by Minfeng Chen
This map shows the geographic impact of Minfeng Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minfeng Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minfeng Chen more than expected).
Fields of papers citing papers by Minfeng Chen
This network shows the impact of papers produced by Minfeng Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minfeng Chen. The network helps show where Minfeng Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Minfeng Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 84 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | m6A modification: recent advances, anticancer targeted drug discovery and beyond Hit paper breakdown → | 2022 | 265 |
| 2 | Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer Hit paper breakdown → | 2021 | 260 |
| 3 | 2013 | 192 | |
| 4 | 2019 | 123 | |
| 5 | 2022 | 110 | |
| 6 | 2019 | 82 | |
| 7 | 2017 | 59 | |
| 8 | 2023 | 51 | |
| 9 | 2022 | 51 | |
| 10 | 2010 | 51 | |
| 11 | 2023 | 50 | |
| 12 | 2014 | 50 | |
| 13 | 2023 | 45 | |
| 14 | 2015 | 42 | |
| 15 | 2016 | 39 | |
| 16 | 2016 | 38 | |
| 17 | 2023 | 36 | |
| 18 | 2021 | 36 | |
| 19 | 2020 | 35 | |
| 20 | 2019 | 32 |
About Minfeng Chen
Minfeng Chen is a scholar working on Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine, Oncology and Surgery, having authored 84 papers that have together received 2.3k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (11 papers), Cancer-related molecular mechanisms research (8 papers), Angiogenesis and VEGF in Cancer (5 papers), Ferroptosis and cancer prognosis (5 papers), Prostate Cancer Diagnosis and Treatment (5 papers), Cancer, Hypoxia, and Metabolism (5 papers), Prostate Cancer Treatment and Research (4 papers) and Peptidase Inhibition and Analysis (4 papers). The work is most often cited by research in Cancer Research (514 citations), Molecular Biology (1.1k citations), Oncology (353 citations), Pharmacology (111 citations) and Immunology (232 citations). Minfeng Chen has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Dongmei Zhang, Wen‐Cai Ye, Lijuan Deng, Xiongbing Zu, Zhe‐Sheng Chen, Maohua Huang, Ming Qi, Jinbo Chen, Huihui Zhang and Wen-Yu Lyu. Their work appears in journals such as European Journal of Nuclear Medicine and Molecular Imaging, BMC Cancer, Orphanet Journal of Rare Diseases, Cancer Letters and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.